Singapore: AOP Orphan, a pharmaceutical company in the field of rare diseases, has launched world's first drug approved ...
Singapore: Three quarters of the population of China and India are diabetic. This translates to a patient pool of nearly...
Tokyo: PeptiDream Inc., a Tokyo-based biopharmaceutical company, has signed a multi-target discovery and optimization co...
Singapore: 3SBio, China-based biotechnology company focused on researching, developing, manufacturing and marketing biop...
Singapore: US based Roivant Neurosciences, a biopharmaceutical company engaged in the development and commercialization ...
Singapore: Korea based ImmunoMet Therapeutics, a biotechnology company developing innovative drugs for the treatment of ...
Bangalore: AstraZeneca and Cellworks have announced a collaboration, to speed the design of novel combination therapies ...
Singapore: Researchers from the University of Queensland in Australia have identified that existing drugs could be repur...
Singapore: Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cance...
‎Singapore: Mundipharma, an Asian pharmaceutical company, has launched Flutiform (fluticasone propionate/formotero...
Singapore: Alcon, the global leader in eye care and a division of Novartis, has recieved US FDA approval for Simbrinza s...
Singapore: Merck's grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis...
Singapore: Japan-based Astellas Pharma and US-based FibroGen initiated a phase II clinical study in Japan of ASP1517/FG-...
Singapore: Australian immuno-oncology company, Minomic International, is set to launch the first human study of its nove...
US-based Sprout Pharmaceuticals gained USFDA's approval for Addyi, whose chemical name is Flibanserin, created to enhanc...
Singapore: Australian infectious disease therapy and vaccine development company, BioDiem, has received allowance of Jap...
Singapore: Gilead Sciences has submitted a new drug application (NDA) to the US FDA for the approval of Idelalisib, an i...
Singapore: Taiwan based TWi Pharmaceutical's drug candidate AC-203 has received designation of rare disease drug by Taiw...
